NASDAQ:BGM - Nasdaq - KYG7307E1237 - Common Stock - Currency: USD
BGM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. BGM has a great financial health rating, but its profitability evaluates not so good. BGM is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -2.72% | ||
ROE | -3.38% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 16.39% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 65.36 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.39 | ||
Quick Ratio | 2.82 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 1592.1 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:BGM (5/2/2025, 8:00:01 PM)
11.7
+0.4 (+3.54%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 45.32 | ||
P/FCF | N/A | ||
P/OCF | 2090.18 | ||
P/B | 26.61 | ||
P/tB | 29.77 | ||
EV/EBITDA | 1592.1 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -2.72% | ||
ROE | -3.38% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 16.39% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 106.56% | ||
Cap/Sales | 5.25% | ||
Interest Coverage | N/A | ||
Cash Conversion | 80.81% | ||
Profit Quality | N/A | ||
Current Ratio | 3.39 | ||
Quick Ratio | 2.82 | ||
Altman-Z | 65.36 |